Gilead loses hepatitis C patent case

A US federal jury has upheld a Merck & Co claim against Gilead Sciences that its hepatitis C drug sofosbuvir infringed two Merck patents, according to Reuters.

Sofosbuvir is in both Harvoni and Sovaldi, two of the high-priced Gilead preparations which were PBS-listed in Australia on March 1.

According to court papers, Merck contacted Gilead in 2013 saying the active ingredient in sofosbuvir infringed Merck's patents.

Sovaldi and Harvoni brought in over

Latest

Trending